Introduction {#section1-2333794X19862712}
============

Recent studies have shown that the prevalence and incidence of neuroendocrine tumors (NETs) have been gradually increasing over the last few decades. Dasari et al used the Surveillance Epidemiology, and End Results (SEER) to analyze NET patients from 1973 to 2012.^[@bibr1-2333794X19862712]^ They reported an approximately 6-fold increase in incidence over the past 4 decades. This steady rise can be a result of improved diagnostics and increased detection of the disease.

Neuroendocrine tumors are often considered benign but carry a definite potential for malignant transformation. Due to the indolent nature of the disease, diagnosis is often delayed. It is reported that 10% to 20% of children and young adolescents present with metastatic disease at presentation.^[@bibr2-2333794X19862712],[@bibr3-2333794X19862712]^ Early detection is the key since surgical resection can be curative. Most early-stage surgically resected patients show durable relapse-free survival; however, there is a risk of relapse, which is linked to improper excision of the tumor and presence of locoregional or lymphovascular involvement at the time of initial presentation.^[@bibr3-2333794X19862712]^ Lobeck et al reported 10% perineural invasion and about 3% lymphovascular invasion in their series of pediatric appendectomies for NETs.^[@bibr4-2333794X19862712]^ NETs can originate in various organ system but gastrointestinal tract and lung are by far the most common locations. Presenting symptoms can be absent or nonspecific, including weight loss and abdominal pain. These clinical symptoms can be overlooked by physicians or patients for many years.^[@bibr5-2333794X19862712]^

In 2000, the World Health Organization (WHO) adopted a universal system of diagnosing NETs.^[@bibr6-2333794X19862712]^ Prior to this, there was ambiguity in diagnostic criteria. More appropriate and consistent terminology to report the diverse presentations of NETs into well-differentiated NETs and poorly differentiated neuroendocrine carcinoma were introduced.^[@bibr7-2333794X19862712],[@bibr8-2333794X19862712]^ The 2010 WHO classification further stratified the diagnosis of NETs. These tumors were categorized into grade I, grade II, or grade III based on mitotic count and/or Ki-67 proliferation index. The Ki-67 index of grade I tumor is ≤2%, for grade II it is 3% to 20%, and for grade III it is ≥20%.^[@bibr9-2333794X19862712],[@bibr10-2333794X19862712]^ Grade III poorly differentiated carcinomas were recognized to be highly aggressive with unfavorable outcomes. Recent data suggest that not all grade III NETs portend a poor prognosis. Investigators were able to stratify grade III neuroendocrine neoplasms into well-differentiated and poorly differentiated subgroups with stark differences in survival statistics between these 2 groups.^[@bibr11-2333794X19862712][@bibr12-2333794X19862712]-[@bibr13-2333794X19862712]^ This led to the reclassification of grade III tumors into 2 distinct subcategories (well-differentiated grade III and poorly differentiated grade III) in the 2017 WHO classification.^[@bibr14-2333794X19862712]^ Well-differentiated neoplasms are termed "neuroendocrine tumors," while poorly differentiated neoplasms are designated as "neuroendocrine carcinomas." Due to the heterogeneous nature of grade III tumors, this new classification system enables treating physician to manage these grade III subentities very differently. Our subsequent discussion will be focused on the pediatric population.

Prevalence and Incidence of NETs in Pediatric Population {#section2-2333794X19862712}
========================================================

There is an overall rise in NET incidence since the last few decades. Dasari et al reported a rise in incidence rate from 1.09 (1973) to 6.98 per 100 000 (2012).^[@bibr1-2333794X19862712]^ A recent analysis of the Kentucky Cancer Registry evaluating 6179 NET patients found a similar linear increase in incidence rate from 3.1 (1995) to 7.1 (2015) per 100 000 population.^[@bibr15-2333794X19862712]^

Gastroenteropancreatic (GEP) neuroendocrine neoplasms in the United States have increased by 720% in incidence, as well as 213% to 286% in prevalence over the past 40 years.^[@bibr16-2333794X19862712],[@bibr17-2333794X19862712]^ Epidemiology data suggest the greatest increase in stomach and rectal GEP-NETs, whereas appendiceal NET was the sole site that showed a decreased in prevalence.

The data specific to pediatric NET epidemiology are limited due to its rare occurrence in this population. Navalkele et al reported the incidence rates of the most common sites of malignant NETs in children and young adults and found lung, breast, and appendix incidence to be 0.6, 0.5, and 0.4 per million population, respectively.^[@bibr18-2333794X19862712]^ The estimated incidence is about 2.8 cases per million and estimated prevalence count is 7724.^[@bibr18-2333794X19862712]^

According to Sarvida and O'Dorisio, the incidence rates of lung, breast, and appendix NET in children and young adults under the age of 30 years were 0.6, 0.6, and 0.5 per million, respectively.^[@bibr3-2333794X19862712]^ All other sites including colon, small cell carcinoma, and pancreatic NETs had an incidence rate of \<0.1 per million. Surprisingly, the majority of their study cohort had bronchial NETs (28%), followed by appendiceal NET (18%).

Presentation of NETs in Pediatric Population {#section3-2333794X19862712}
============================================

Similar to the adult patient population, NETs have the potential to affect any organ system in the pediatric age group. Midgut NET forms the most common site of origin.^[@bibr8-2333794X19862712],[@bibr19-2333794X19862712],[@bibr20-2333794X19862712]^ Within midgut NETs, appendix seems to be reported the most common site of origin in the pediatric population. Tumors of the appendix can clinically present as acute appendicitis or abdominal pain. While it is not uncommon for gastrointestinal NETs to present with carcinoid syndrome---a symptom complex of diarrhea, flushing, and wheezing due to the secretion of vasoactive substances secreted by the tumor---carcinoid syndrome is uncommon in pediatric age groups. This could be due to the low incidence of hepatic metastases in pediatric NET patients.^[@bibr8-2333794X19862712],[@bibr19-2333794X19862712],[@bibr21-2333794X19862712]^ However, it is worth noting that there have been some reports of clinical presentations of carcinoid syndrome in a younger age group, though these findings are not common.^[@bibr22-2333794X19862712]^

Bronchial NETs are considered the most frequent primary pulmonary tumors in children and adolescents.^[@bibr22-2333794X19862712]^ Diagnosing these neoplasms based on clinical features is difficult due to lack of symptoms at an early stage. Symptoms of cough and wheezing are often attributed to other reactive airway diseases. The patient can also present with recurrent pneumonitis or respiratory distress.^[@bibr23-2333794X19862712]^ Wang et al reported a series of 17 bronchial NETs in the pediatric age group.^[@bibr22-2333794X19862712]^ Median age at presentation was found to be 17 years in their study cohort. Broaddus et al had also concluded that the lung was the most common extra-appendiceal NET primary site with 6 out of 13 patients presenting with BCTs (bronchopulmonary carcinoid tumors) with the mean age range of 12.7 years.^[@bibr21-2333794X19862712]^ A 2017 study that researched 45 cases of reported carcinoid tumors in patients ranging from ages 7 to 21 years found that appendiceal tumors comprised 80% of the diagnoses, followed by bronchial carcinoid tumors at 11%.^[@bibr24-2333794X19862712]^

It is observed that there is female dominance in pediatric reports of NETs. A short review of 14 appendiceal carcinoid tumors found a female preponderance (64.3%).^[@bibr25-2333794X19862712]^ This was also consistent with recent SEER database analysis of NETs, wherein 34 233 out of total 64 971 NET cases (52.7%) were females.^[@bibr1-2333794X19862712]^ Pawa et al also reported 60.5% female predominance in appendiceal NETs.^[@bibr26-2333794X19862712]^

Diagnosis and Staging of NETs {#section4-2333794X19862712}
=============================

Accurate staging of NETs is imperative for optimal clinical management. The 2017 WHO classification of NETs is the adopted framework for many research studies. It grades tumors based on their biological behavior and histology. NETs can also be categorized as functional or nonfunctional. Functional tumors remain hormonally active and exhibit clinical symptoms while nonfunctional tumors do not. This is a key differentiation to make due to important differences in the management of a functional NET versus a non-functional NET.^[@bibr27-2333794X19862712]^

Ki-67 expression identifies proliferating tumor cells, atypical cytology, and tumor grade. Chromogranin A (CgA) directly correlates to the high number of secretory vessels of NETs, which makes increased serum levels a useful marker for these tumors, especially low-grade NETs. However, poor sensitivity and specificity of CgA pose limitations with routine use for disease monitoring. Twenty-four-hour urine 5-hydroxyindoleacetic acid (5-HIAA) is another useful biomarker that can be measured to confirm serotonin-producing NET and also help in disease monitoring. Gut et al compared the specificity and sensitivity of CgA with 5-HIAA urine test. The 5-HIAA marker had higher specificity (100%) than CgA (86%), but a lower sensitivity (35%) to CgA (68%).^[@bibr28-2333794X19862712]^ The variations in these NET biomarkers makes it difficult to infer a definitive diagnosis, which requires the need for advanced diagnostic modalities.

Radiology Studies of NETs {#section5-2333794X19862712}
=========================

Proper imaging is key to localize, grade, and confirm diagnoses of NETs. Traditional modalities include contrast-enhanced computed tomography (CT) scans and magnetic resonance imaging (MRI), positron emission tomography (PET) scans, and somatostatin receptor scintigraphy (Octreo scan). Contrast-enhanced CT scan has a broad specificity range of 3% to 100% and a sensitivity range of 63%to 82% when detecting NETs \<2 cm.^[@bibr29-2333794X19862712]^ Neoplasms \<2 cm were also found to have decreased sensitivity with CT. The specificity (75%) and sensitivity (85%) of MRI in patients with pancreatic NETs were also tested. MRI pancreatic protocol can help in imaging pancreatic NETs and guide surgical candidacy. PET scan with ^18^F-fluorodeoxyglucose (FDG) has limitations in being unable to detect well-differentiated and low metabolically active NETs. The limitations of these conventional techniques have led to a recent Food and Drug Administration (FDA)-approved imaging modality with impressive diagnostic results: ^68^Ga-DOTATATE PET/CT.

^68^Ga-DOTATATE, ^68^Ga-DOTATOC, and ^68^Ga-DOTANOC are the most common peptides that vary in affinity to different somatostatin receptors when detecting well-differentiated NETs.^[@bibr30-2333794X19862712]^ ^68^Ga-DOTATATE PET/CT has been very impactful with its high sensitivity in detecting metastases/lesions, identifying NETs of unknown primary sites, and influencing management plans. This diagnostic tool surpasses conventional diagnostic imaging techniques.

Sadowski et al did a prospective study on patients with GEP NETs, comparing ^68^Ga-DOTATATE PET/CT with ^111^In-pentetreotide single-photon emission CT (SPECT/CT) and anatomic imaging (CT/MRI).^[@bibr31-2333794X19862712]^ ^68^Ga-DOTATATE was able to detect a total of 847 lesions, while ^111^In-pentetreotide SPECT/CT detected 275 and CT/MRI detected 404 in the pancreas, liver, bowel, lung, abdomen, and bone.^[@bibr31-2333794X19862712]^ The DOTATATE scan was also performed on 68 patients with metastatic NETs and unknown primary sites. The scan successfully detected primary sites in 40/68 patients. Prasad et al support these findings by locating primary sites in 59% of patients via the scan.^[@bibr32-2333794X19862712],[@bibr33-2333794X19862712]^ Schreiter et al also detected 45.5% primary sites using ^68^Ga-DOTATOC and only 8% using In-111 DTPA octreotide SPECT/CT.^[@bibr34-2333794X19862712]^ The efficacy of the DOTATATE scan is a breakthrough for NETs. ^68^Ga-DOTATATE PET/CT is also instrumental in detecting primary sites when conventional imaging fails. NETs of unknown primary make up 10% to 13% of all NETs.^[@bibr32-2333794X19862712]^ Detection of primary sites can influence surgical resections and management options.

Studies suggest ^68^Ga-DOTATATE PET/CT should be considered a first-line diagnostic tool in adult and pediatric patient populations. Goel et al analyzed 30 NET pediatric patients (median age = 7.6 years) with 13 presenting with bone metastases.^[@bibr35-2333794X19862712]^ ^68^Ga-DOTATATE PET/CT was able to detect metastasis in all 13 patients, while conventional CT scan could only detect lesions in 9 patients.^[@bibr35-2333794X19862712]^ As far as lesions, a total of 225 bone lesions were found with the DOTATATE scan, while CT only found 84. Jha et al evaluated the lesion detection rates for pediatric patients presenting with pheochromocytomas.^[@bibr36-2333794X19862712]^ ^68^Ga-DOTATATE PET/CT, F-FDG PET/CT, and conventional CT/MRI detection rates were 93.5%, 79.4%, and 73.8%, respectively.^[@bibr36-2333794X19862712]^ McGowan et al used the DOTATATE scan on a 13-year-old boy to detect residual adrenal tissue that was missed with an MRI or F-FDG-PET scan.^[@bibr37-2333794X19862712]^ This discovery led to changes in the management plan to resect the newfound tumor.

^68^Ga-DOTATATE shows superiority over most imaging techniques, has low exposure to radiation, low toxicity, fast administration/clearance time, and is cost-effective. The scan is a reliable tool to optimize treatment regimens for pediatric patients. This is especially true because young patients are less likely to complain of pain or show symptoms, making it difficult to accurately assess them. A new management plan was implemented in a 4-year-old child whose neuroblastoma was revealed with a DOTATATE scan, but not a CT scan.^[@bibr35-2333794X19862712]^ The DOTATATE scan also identified bone metastases in another adolescent patient, which advanced his disease from stage 1 to stage 4.^[@bibr35-2333794X19862712]^ These studies support the clinical significance and evident benefit in using the ^68^Ga-DOTATATE PET/CT diagnostically for pediatric and adult patients.

Treatment of NETs {#section6-2333794X19862712}
=================

Surgical Management of NETs {#section7-2333794X19862712}
---------------------------

Clinical management of NETs largely depends on tumor location, tumor grade, tumor growth rate, and the extent of disease and symptoms. Surgical resection is conventionally considered first-line therapy in early-stage disease due to its excellent long-term outcomes.^[@bibr38-2333794X19862712][@bibr39-2333794X19862712]-[@bibr40-2333794X19862712]^ Lobeck et al evaluated 30 pediatric appendectomies and found postoperative surveillance (36 months) to be normal with no further treatment required.^[@bibr4-2333794X19862712],[@bibr41-2333794X19862712],[@bibr42-2333794X19862712]^ Due to the successful outcomes of these procedures, there is an incentive to find ideal strategies for surgery. For example, Bholah and Bunchman reviewed pediatric pheochromocytoma and paragangliomas and found a shift in utilizing laparoscopy over laparotomy in both pediatric and adult populations.^[@bibr43-2333794X19862712]^ Continuous advances in surgical approach are imperative to maintaining curative results with minimal morbidities.

Non-Surgical Management of NETs {#section8-2333794X19862712}
-------------------------------

Though surgical intervention is favored as first-line treatment for the early-stage disease, metastatic NETs are generally deemed unresectable. Nonsurgical treatment modalities include somatostatin analogs, molecularly targeted therapy, cytotoxic chemotherapy, and peptide receptor radionuclide therapy (PRRT). NETs are unique in their increased expression of somatostatin receptors. Targeted therapy through octreotide, a somatostatin analog, has shown antitumor and cytostatic effects.^[@bibr44-2333794X19862712]^ It is also linked to increased survival in patients with metastatic midgut carcinoid tumors.^[@bibr41-2333794X19862712],[@bibr45-2333794X19862712],[@bibr46-2333794X19862712]^ Molecular targeted therapy targets growth factors, receptors, and signaling cascades to inhibit tumor growth.^[@bibr46-2333794X19862712]^ Traditionally, cytotoxic chemotherapy has limited benefits in treating unresectable cancers; however, there has been some progress. Temozolomide administration in patients with bronchial and thymic neuroendocrine neoplasms showed a clinical benefit rate of 71% and 90%, respectively.^[@bibr47-2333794X19862712]^ Recently reported randomized phase II clinical trial confirmed both progression-free survival (PFS) as well as overall survival benefit with combination capecitabine and temozolomide in pancreatic NET patients.^[@bibr48-2333794X19862712]^ Combination therapies have also proven to be very effective in the management of NETs. Pediatric and adult patients with NET malignancies have responded well to chemotherapy adjunct with cyclophosphamide, vincristine, and dacarbazine.^[@bibr43-2333794X19862712]^ Out of 11 patients, 5 had a partial response, 5 had stable disease, and 1 showed complete remission.

Molecular targeted therapy with everolimus is now FDA approved for the metastatic progressive NET of gastrointestinal tract and bronchial origin. Everolimus is an oral mTOR (mammalian target of rapamycin) inhibitor. This approval was based on a large international randomized phase III clinical trial (RADIANT 4) and confirmed PFS benefit over control arm.^[@bibr49-2333794X19862712]^

Last, PRRT has revolutionized the treatment of NETs. PRRT has been widely accepted as a standard treatment for progressive NETs in Europe for about 10 years but PRRT was deemed experimental in the United States due to lack of prospective randomized data. In 2018, the FDA finally approved PRRT as the standard of care treatment for progressive midgut NETs who had progressed on frontline therapy. The FDA approval was based on positive findings from a large randomized phase III clinical trial (NETTER-1).^[@bibr50-2333794X19862712]^ The experimental arm (177 Lutetium DOTATATE) had 65% PFS at 20 months as compared with 10.8% for control (Octreotide) arm. Last but not least, there has been strides in the management of NET supportive care as well. The FDA approved first in its class oral tryptophan hydroxylase inhibitor, which inhibits the production of serotonin. The FDA approval was based on TELESTAR trial, which was a phase III randomized placebo-controlled trial and confirmed improvement in carcinoid diarrhea and reduction of urinary 5-HIAA in treatment arm versus placebo arm.^[@bibr51-2333794X19862712]^

Conclusion {#section9-2333794X19862712}
==========

Neuroendocrine tumors account for a small percentage of pediatric tumors; however, their diagnosis and prevention can be challenging due to their indolent course and vague symptoms. Improvement in diagnostic modalities (Gallium 68 DOTATATE) has markedly improved diagnostic sensitivity and specificity. Awareness of this rare tumor has resulted in accelerated therapeutic development and recent FDA approvals of everolimus, telotristat, and PRRT are a testament to ongoing research efforts. However, most if not all research is focused on adult NETs, and pediatric NETs continue to remain an area of unmet medical need. Understanding the parallel between childhood NETs and genetic variations with MEN1 hereditary syndromes could be helpful in earlier intervention.^[@bibr52-2333794X19862712]^ It is important to explore therapeutic treatments and validate recently approved NET treatments in the pediatric patient population.
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